Indegene's profit falls despite sequential revenue and margin gains
Lower other income and higher interest outweighed operating improvement, while management said the wage increase is fully reflected in the base.
Filed 29 Oct 2026, 19:40 IST · after market close · Indegene Ltd (INDGN)
Key takeaways
- Consolidated revenue rose +5.57% sequentially to Rs 1,122.3 cr, while expenses grew +5.37%.
- Net profit fell -3.36% sequentially to Rs 112.3 cr as other income dropped -48.28% and interest rose +7.81%.
- Operating margin improved 0.16 percentage points to 16.55%, but remained 3.11 percentage points below the 19.66% median for 26 reported healthcare peers.
Price around the results
Revenue growth did not translate into higher profit
Indegene's consolidated revenue increased +5.57% sequentially, and expenses grew slightly slower at +5.37%, lifting operating profit by +6.60%. Profit before tax nevertheless declined -3.47% because other income fell -48.28% and interest increased +7.81%; depreciation also rose +5.22%. The lower tax rate, down 0.09 percentage points to 23.81%, did not offset those pressures.
Margin edged up, but remains below the healthcare peer median
Operating margin expanded 0.16 percentage points to 16.55% because revenue growth outpaced expense growth. Other income still accounted for 10.18% of profit before tax, making the quarter's earnings less purely operational. Indegene's margin was 3.11 percentage points below the 19.66% median among 26 healthcare peers that had reported.
Management flags wage absorption and GenAI initiatives
Management said the annual wage increase is now fully reflected in the cost base, with improvement levers building into Q4. The company told investors it is pursuing a two-part GenAI strategy focused on accelerating client value while building future capabilities. Management also said the US rate hike reduced PBT yield by 90 basis points and PAT yield by 70 basis points in Q2 FY27.
Results were filed after market close
The consolidated results were filed at 19:40 IST on 29 October 2026, after the market closed. No post-results stock reaction is covered here because the filing was made after close.
Q2FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q2FY27 | Q1FY27 | QoQ |
|---|---|---|---|
| Revenue | ₹1,122 cr | ₹1,063 cr | +5.57% |
| Other income | ₹15 cr | ₹29 cr | -48.28% |
| Expenses | ₹937 cr | ₹889 cr | +5.37% |
| Operating profit | ₹186 cr | ₹174 cr | +6.60% |
| Operating margin (%) | 16.55% | 16.39% | — |
| Interest | ₹7 cr | ₹6 cr | +7.81% |
| Depreciation | ₹46 cr | ₹44 cr | +5.22% |
| Profit before tax | ₹147 cr | ₹153 cr | -3.47% |
| Tax | ₹35 cr | ₹37 cr | -3.84% |
| Net profit | ₹112 cr | ₹116 cr | -3.36% |
| EPS (₹) | ₹4.67 | ₹4.84 | -3.51% |
Operating margin of 16.55% compares with a Healthcare sector median of 19.66% across 26 peers that have reported Q2FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- The annual wage increase is fully reflected in the base, with improvement levers building into Q4.
New initiatives
- Indegene is pursuing a dual-pronged GenAI strategy to accelerate client value while building future capabilities.
Problems & risks
- The US rate hike caused a 90-basis-point PBT yield impact and a 70-basis-point PAT impact in Q2 FY27.
What to watch
- Whether operating margin holds above 16.55% in the next quarter.
- Whether expense growth remains below the +5.57% sequential revenue growth recorded in Q2FY27.
- Whether other income's contribution to profit before tax moves from 10.18%.